Search

Displaying results 2591 - 2600 of 6835 in total
  1. Drug

    Butoconazole

    go.drugbank.com/drugs/DB00639
    Approved

    Butoconazole is an imidazole antifungal used in gynecology.

  2. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    Biphentin was designed to be an alternative to separate doses of immediate-release (IR) methylphenidate by providing a biphasic concentration-time profile when given as a single dose. … [A177541, A177544] Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity.

  3. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  4. Drug

    Icaridin

    go.drugbank.com/drugs/DB14074
    Investigational

    It is considered to be the first choice of repellent by the Public Health Agency of Canada’s Canadian Advisory Committee on Tropical Medicine and Travel for travelers six months to 12 years of age [A39203 … Icaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595].

  5. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia.

  6. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. … options for critically ill hypotensive patients who do not adequately respond to currently available therapies.

  7. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases. … Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

  8. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. … [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]

  9. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

  10. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease.

    Synonyms: Diosmetin 7-O-rutinoside